Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aim: There are limited comparative studies of ceftazidime/avibactam (CAZ/AVI) vs. polymyxin B (PMB) for carbapenem-resistant organisms (CRO) infections. The aim of this study was to compare the efficacy and safety of CAZ/AVI and PMB in treating CRO infections.
Methods: This single-centre, retrospective cohort study with propensity score-matching (PSM) involved adult patients with CRO infections. Patients who received the CAZ/AVI-based regimen were included in the cohort group; those prescribed with the PMB-based regimen were included in the control group. The primary outcome was 28-day all-cause mortality.
Results: Among 298 eligible patients, 96 patients in each group were included in the PSM cohort. The CAZ/AVI group showed no improvement in 28-day or 14-day all-cause mortality, nor in 14-day clinical response, compared to the PMB group. However, the CAZ/AVI-based regimen was associated with higher 14-day clinical response rates than the PMB-based regimen in subgroups with carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections and monotherapy. The CAZ/AVI group achieved greater CRO eradication than the PMB group (crude odds ratio [OR], 1.658; 95% confidence interval [CI], 1.108-2.480; P = 0.014; adjusted OR, 1.718; 95% CI, 1.055-2.798; P = 0.030). This advantage in CRO eradication with CAZ/AVI was consistent in most subgroups, including septic shock, bloodstream infection and lower respiratory tract infection. The CAZ/AVI and PMB groups had comparable nephrotoxicity (crude OR, 0.577; 95% CI, 0.306-1.089; P = 0.090; adjusted OR, 0.741; 95% CI, 0.361-1.521; P = 0.414).
Conclusion: CAZ/AVI-based and PMB-based regimens demonstrated similar clinical efficacy and nephrotoxicity in treating CRO infections. However, CAZ/AVI was superior to PMB in CRO eradication and treating CRPA infections. CAZ/AVI monotherapy was more effective than PMB monotherapy for CRO infections.
Trial Registration: ChiCTR2300078790 prospectively registered on 19 Dec 2023 (https://www.chictr.org.cn).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2024.107418 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis.
Ann Pharmacother
July 2025
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Objective: To compare the efficacy and safety of ceftriaxone (CRO) 1 g intravenously (IV) daily to higher doses for treating non-central nervous system (CNS) infections in adults.
Data Sources: PubMed, Embase, Scopus, and Web of Science were used. A search was run from database inception to August 8, 2023 and rerun May 12, 2025.
Enhanced barrier precautions to prevent transmission of and Carbapenem-resistant organisms in nursing home chronic ventilator units.
Infect Control Hosp Epidemiol
August 2025
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Objective: Assess the feasibility and effect of Enhanced Barrier Precautions (EBP) on the transmission of (SA) and carbapenem-resistant organisms (CRO) among residents in nursing home chronic ventilator units (NH-CVU).
Design: Pre-post interventional study.
Setting: Two community-based nursing homes with CVUs in Maryland.
Efficacy analysis of intraventricular/intrathecal polymyxin B sulphate injections in the treatment of Post-neurosurgical CNS infections in neurocritical ill patients: a prospective observational study.
Eur J Clin Microbiol Infect Dis
August 2025
Department of neurosurgery & neurocritical care, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.
Background: Intracranial infections due to carbapenem-resistant organisms (CRO) pose substantial challenges in the neurosurgical intensive care unit (NICU). The increasing prevalence of infections caused by carbapenem-resistant Acinetobacter (CRAB) and carbapenem-resistant Klebsiella pneumoniae (CRKP) necessitates the development of novel treatment strategies. This prospective observational study aims to evaluate the efficacy and safety of intraventricular/intrathecal polymyxin B sulfate (PBS) in NICU patients after neurosurgery.
View Article and Find Full Text PDFForecasting antimicrobial resistance in China using a hybrid ARIMA-GM(1,1) model.
BMC Infect Dis
August 2025
Chinese People's Liberation Army Center for Disease Control and Prevention, Beijing, China.
Objective: To evaluate the application value of the ARIMA-GM(1,1) combined model in predicting the resistance rates of key drug-resistant bacteria in China, providing a scientific basis for optimizing antimicrobial management strategies.
Methods: Based on data from the China Antibacterial Resistance Surveillance Network from 2014 to 2023, we selected six types of key drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and cefotaxime/ceftriaxone-resistant Klebsiella pneumoniae (CTX/CRO-R-KP), to construct the ARIMA-GM(1,1) combined model. The model performance was evaluated using five metrics: Mean Squared Error (MSE), Root Mean Squared Error (RMSE), Mean Absolute Error (MAE), Mean Absolute Percentage Error (MAPE) and R, and the resistance rate trends for 2024-2028 were predicted.
The function of the HtrA protease in maintaining homeostasis of the human pathogen Helicobacter pylori.
Microb Pathog
August 2025
Department of General and Medical Biochemistry, Faculty of Biology, University of Gdansk, Wita Stwosza 59, 80-308, Gdansk, Poland. Electronic address:
Helicobacter pylori is a Gram-negative bacterium known to cause persistent infections in humans. HtrA protease is one of the most important secreted virulence factors of this pathogen and is responsible for damaging intercellular junctions between the gastric epithelial cells. Although this protein is regarded as essential in H.
View Article and Find Full Text PDF